Viridian Therapeutics (VRDN) Projected to Release Earnings on Wednesday

Viridian Therapeutics (NASDAQ:VRDN) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Viridian Therapeutics to announce earnings of ($1.02) per share and revenue of $4.72 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. On average, analysts expect Viridian Therapeutics to post ($4.07) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Viridian Therapeutics Stock Up 2.6%

NASDAQ:VRDN opened at $25.30 on Tuesday. The firm has a market capitalization of $2.87 billion, a P/E ratio of -7.51 and a beta of 1.11. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29. The company’s fifty day moving average price is $21.68 and its 200-day moving average price is $21.91. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on VRDN shares. Wall Street Zen lowered shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, October 4th. Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 14th. Royal Bank Of Canada boosted their price objective on Viridian Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Finally, Truist Financial boosted their price objective on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.92.

Insider Buying and Selling at Viridian Therapeutics

In other news, insider Jennifer Tousignant sold 14,212 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.40% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.